Tested CPX-351 with gemtuzumab for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70, and you have newly diagnosed AML
- Your AML cells must have CD33, as shown by a lab test (flow cytometry or biopsy testing)
- You can likely tolerate intensive chemotherapy (your health status score is 2 or less)
- You must have good heart, liver, and other organ function for study treatment
- If you are able to have a pregnancy, you must use very effective birth control and have a negative pregnancy test right before treatment
- You must not have certain exclusions like active hepatitis infection, known FLT3 gene mutations, or past AML treatment other than limited exceptions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.